Suzanne J Grant, Shelley Kay, Judith Lacey, Sanjeev Kumar, Kim Kerin-Ayres, Justine Stehn, Maria Gonzalez, Sandra Templeton, Gillian Heller, Jane Cockburn, Sara Wahlroos, Ashanya Malalasekera, Cindy Mak, Susannah Graham
INTRODUCTION: Neoadjuvant therapy has become a standard treatment for patients with stage II/III HER2 positive and triple negative breast cancer, and in well-selected patients with locally advanced and borderline resectable high risk, luminal B breast cancer. Side effects of neoadjuvant therapy, such as fatigue, cardiotoxicity, neurotoxicity, anxiety, insomnia, vasomotor symptoms, gastrointestinal disturbance as well as a raft of immune-related adverse events, may impact treatment tolerance, long-term outcomes, and quality of life...
March 20, 2024: BMJ Open